The “EPA3G” branded supplement is available in sachet form and contains almost three grams of the omega-3 oil eicosapentaenoic acid (EPA), which can be administered as a drinkable emulsion once a day.
According to the company, the format overcomes current problems with omega-3 consumption, such as: B. the dosage required to achieve significant health benefits and the lack of alternatives to bulky, hard-to-swallow capsules.
“With this agreement, people now have a differentiated, value-added omega-3 product that is effective and easy to use,” said Luciano Conde, CEO of Noventure.
“We are excited to partner with Azur. Together, we will continue to build strong partnerships based on a shared understanding of user needs and pursue market opportunities as we grow together.”
EPA and DHA market.
Under the agreement, Noventure will acquire the rights to license EPA3G to companies with “marketing expertise and knowledge of high-end nutritional supplements”. .
Noventure may exercise these license rights to all EU members and associated countries, the United Kingdom, the Balkans, Russia, Ukraine, the Eurasian countries, Mexico, Taiwan and several African countries. Financial details of the agreement were not disclosed.
Regarding the global EPA and DHA market, which is expected to grow 8.26% in the period 2020-2025, Julio Boza, CEO of Azur, cites the reasons for this growth as “the increasing prevalence of lifestyle diseases and people back who choose preventive health measures. .
“Consumer desire for high potency and bioavailability has also caused manufacturers to look for more concentrated forms to provide more effective doses of EPA. We are very happy to work with Noventure. .
We believe this technology will enable people to meet their omega-3 needs in a convenient, drinkable format. This is a great example of transforming brilliant science and technology into groundbreaking, sustainable commercial solutions and an example of how to work together and grow together. “